...
首页> 外文期刊>Asian Pacific Journal of Cancer Prevention >Expression of Ki67 in Papillary Thyroid Microcarcinoma and its Clinical Significance
【24h】

Expression of Ki67 in Papillary Thyroid Microcarcinoma and its Clinical Significance

机译:KI67在乳头状甲状腺微癌中的表达及其临床意义

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Purpose: To investigate the expression of Ki67 protein in papillary thyroid microcarcinoma(PTMC), and to analyze its clinical significance. Materials and Methods: Ki67 protein expression was evaluated in the tissues of 108 human PTMC and 50 other benign papillary hyperplasia of thyroid specimens using immunohistochemistry. Results: The expression intensity of Ki67 in PTMC and benign papillary hyperplasia of thyroid specimens were and .The positive expression rates were 46.3% and 14%. There were significant differences between these two groups (p 0.05), but these parameters varied with tumor size, invasion by membrane and cervical lymph node metastasis (p0.05 or p0.01). Conclusions: The expression of Ki67 in PTMC was related to tumor size, invasion by membrane and cervical lymph node metastasis, and could be the important indicator for judging clinical progress and estimating prognosis.
机译:目的:探讨Ki67蛋白在乳头状甲状腺微癌(PTMC)中的表达,分析其临床意义。材料和方法:使用免疫组织化学在108人PTMC和50个其他甲状腺标本的其他良性乳头状增生的组织中评价Ki67蛋白表达。结果:甲状腺标本PTMC和良性乳头状增生中的KI67表达强度均为46.3%和14%。这两组之间存在显着差异(P 0.05),但这些参数随肿瘤大小而变化,膜通过膜和颈淋巴结转移而变化(P <0.05或P <0.01)。结论:KI67在PTMC中的表达与肿瘤大小,膜和宫颈淋巴结转移有关,并且可能成为判断临床进度和估算预后的重要指标。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号